CN103687946B - 用于诱导组织再生的肽及其应用 - Google Patents

用于诱导组织再生的肽及其应用 Download PDF

Info

Publication number
CN103687946B
CN103687946B CN201280031164.XA CN201280031164A CN103687946B CN 103687946 B CN103687946 B CN 103687946B CN 201280031164 A CN201280031164 A CN 201280031164A CN 103687946 B CN103687946 B CN 103687946B
Authority
CN
China
Prior art keywords
amino acid
acid sequence
peptide
cells
bone marrow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280031164.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN103687946A (zh
Inventor
玉井克人
山崎尊彦
金崎努
樱井滋
野口由纪子
远藤真弓
滨渕夏美
内藤佳奈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Storm & Co Ltd
University of Osaka NUC
Original Assignee
Osaka University NUC
Genomix Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC, Genomix Co Ltd filed Critical Osaka University NUC
Priority to CN202111352869.9A priority Critical patent/CN114106139B/zh
Priority to CN201710265231.9A priority patent/CN107188948B/zh
Publication of CN103687946A publication Critical patent/CN103687946A/zh
Application granted granted Critical
Publication of CN103687946B publication Critical patent/CN103687946B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
CN201280031164.XA 2011-04-26 2012-04-03 用于诱导组织再生的肽及其应用 Active CN103687946B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202111352869.9A CN114106139B (zh) 2011-04-26 2012-04-03 用于诱导组织再生的肽及其应用
CN201710265231.9A CN107188948B (zh) 2011-04-26 2012-04-03 用于诱导组织再生的肽及其应用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2011-098270 2011-04-26
JP2011098270 2011-04-26
JP2011-219454 2011-10-03
JP2011219454 2011-10-03
PCT/JP2012/059113 WO2012147470A1 (ja) 2011-04-26 2012-04-03 組織再生を誘導するためのペプチドとその利用

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201710265231.9A Division CN107188948B (zh) 2011-04-26 2012-04-03 用于诱导组织再生的肽及其应用
CN202111352869.9A Division CN114106139B (zh) 2011-04-26 2012-04-03 用于诱导组织再生的肽及其应用

Publications (2)

Publication Number Publication Date
CN103687946A CN103687946A (zh) 2014-03-26
CN103687946B true CN103687946B (zh) 2017-05-03

Family

ID=47071995

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202111352869.9A Active CN114106139B (zh) 2011-04-26 2012-04-03 用于诱导组织再生的肽及其应用
CN201280031164.XA Active CN103687946B (zh) 2011-04-26 2012-04-03 用于诱导组织再生的肽及其应用
CN201710265231.9A Active CN107188948B (zh) 2011-04-26 2012-04-03 用于诱导组织再生的肽及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202111352869.9A Active CN114106139B (zh) 2011-04-26 2012-04-03 用于诱导组织再生的肽及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710265231.9A Active CN107188948B (zh) 2011-04-26 2012-04-03 用于诱导组织再生的肽及其应用

Country Status (12)

Country Link
US (4) US10364276B2 (enExample)
EP (2) EP3358011B1 (enExample)
JP (6) JP6069191B2 (enExample)
KR (2) KR101992807B1 (enExample)
CN (3) CN114106139B (enExample)
AU (4) AU2012248676B2 (enExample)
CA (1) CA2834255C (enExample)
DK (2) DK3358011T3 (enExample)
ES (2) ES2684718T3 (enExample)
PL (2) PL3358011T3 (enExample)
PT (2) PT3358011T (enExample)
WO (1) WO2012147470A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2654542T3 (es) 2008-04-30 2018-02-14 Genomix Co., Ltd. Procedimiento de recolección de células funcionales in vivo con alta eficiencia
JP5865703B2 (ja) 2009-10-28 2016-02-17 株式会社ジェノミックス 骨髄間葉系および／または多能性幹細胞の血中動員による組織再生促進剤
MX365899B (es) 2012-10-25 2019-06-19 Univ Osaka Composición farmacéutica que comprende un fragmento de péptido de hmgb1 para usarse en tratamiento de daño a la medula espinal.
SG11201503236RA (en) 2012-10-25 2015-06-29 Genomix Co Ltd Novel method for treating cardiac infarction using hmgb1 fragment
US10961531B2 (en) * 2013-06-05 2021-03-30 Agex Therapeutics, Inc. Compositions and methods for induced tissue regeneration in mammalian species
HUE062186T2 (hu) 2015-05-07 2023-09-28 Univ South Florida Módosított UBE3A gén az Angelman-szindróma génterápiás megközelítésére
CN115433707A (zh) 2015-12-07 2022-12-06 再生疗法有限公司 用于重新衍生不同的多能干细胞衍生的褐色脂肪细胞的方法
CN106995796A (zh) * 2016-01-26 2017-08-01 李建业 基于细胞因子的细胞处理方法、试剂盒及冻干粉
EP3448415A4 (en) * 2016-04-29 2019-11-06 Araim Pharmaceuticals, Inc. TREATMENT-PROOFING PEPTIDES FOR THE PREVENTION AND TREATMENT OF DISEASES AND DISORDERS RELATED TO TISSUE DAMAGE
EP3515419A4 (en) * 2016-09-21 2020-06-10 Stephen H. Thorne High mobility group box i mutant
US11969459B2 (en) 2017-01-27 2024-04-30 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
AU2018250076A1 (en) * 2017-04-07 2019-10-31 Osaka University Therapeutic medicine for fibrous disease
AU2018257071B2 (en) * 2017-04-25 2021-11-11 Shionogi & Co., Ltd. Peptide for inducing regeneration of tissue, and use thereof
JPWO2019107530A1 (ja) * 2017-12-01 2020-11-26 株式会社ステムリム 炎症性腸疾患の治療薬
CN111868231B (zh) * 2017-12-01 2024-05-31 斯特姆里姆有限公司 外胚层间充质干细胞及其产生方法
WO2019156137A1 (ja) 2018-02-08 2019-08-15 株式会社ステムリム 乾癬の治療薬
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
BR112021005982A2 (pt) 2018-10-05 2021-06-29 StemRIM Inc. peptídeo possuindo atividade de mobilização de células-tronco mesenquimais
KR20210082478A (ko) * 2018-10-25 2021-07-05 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 연골 질환의 치료약
EP3949995B1 (en) * 2019-03-26 2024-06-19 Kansai Medical University Educational Corporation Peptide and use thereof
CN109957015A (zh) * 2019-04-01 2019-07-02 中国人民解放军海军军医大学国家肝癌科学中心 一种hmgb1封闭性抗体的制备方法及其应用
CA3157785A1 (en) * 2019-11-12 2021-05-20 Jagdeep Nanchahal Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof
CA3178719A1 (en) * 2020-04-03 2021-10-07 StemRIM Inc. Peptide having mesenchymal stem cell mobilizing activity
US20230173027A1 (en) 2020-04-20 2023-06-08 Shionogi & Co., Ltd. Formulation containing hmgb1 partial peptide
AU2020449867B2 (en) * 2020-04-22 2024-07-18 Chulalongkorn University A composition and a method of rejuvenating DNA and preventing DNA damage
WO2022124626A1 (ko) * 2020-12-07 2022-06-16 사회복지법인 삼성생명공익재단 자가유지능이 향상된 중간엽줄기세포를 선별하는 방법 및 그에 의해 선별된 중간엽줄기세포
WO2022243932A1 (en) * 2021-05-19 2022-11-24 Oxford University Innovation Limited Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof
JPWO2023053384A1 (enExample) 2021-09-30 2023-04-06
CN116983471B (zh) * 2023-06-07 2024-03-08 华中科技大学同济医学院附属协和医院 一种基于α-螺旋双亲性多肽的超分子共组装凝胶的制备方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1671742A (zh) * 2002-07-03 2005-09-21 塔博尔山圣拉弗尔基金中心 Hmgb1在治疗组织损伤和/或促进组织修复中的用途
WO2006024547A2 (en) * 2004-09-03 2006-03-09 Creabilis Therapeutics S.P.A. Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use
EP2301559A1 (en) * 2008-04-30 2011-03-30 Genomix Co., Ltd. Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5238680B2 (enExample) 1972-12-27 1977-09-30
US4732155A (en) 1985-08-27 1988-03-22 The Children's Medical Center Corporation Implantable chemoattractant system
US5658894A (en) 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5661127A (en) 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
JP3018313B2 (ja) 1996-02-23 2000-03-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
DE60042828D1 (de) 1999-07-28 2009-10-08 Univ R Nicotinrezeptoragonisten in stammzellen und vorlaüferzellinduktion
AU1472501A (en) 1999-11-05 2001-05-14 Gerigene Medical Corporation Augmentation and repair of age-related soft tissue defects
EP1114862A3 (de) 1999-11-17 2003-08-06 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
AU4328801A (en) 2000-02-24 2001-09-03 Xcyte Therapies Inc Simultaneous stimulation and concentration of cells
JP3421741B2 (ja) 2000-05-18 2003-06-30 筑波大学長 人工骨髄、血球細胞の増殖方法
US20040191246A1 (en) 2003-02-26 2004-09-30 Connelly Patrick R. Process for in vivo treatment of specific biological targets in bodily fluid
ITMI20010562A1 (it) 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
AU2002304710A1 (en) 2001-04-30 2002-11-11 Switch Biotech Ag Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
DE10121254A1 (de) 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
WO2002092004A2 (en) 2001-05-15 2002-11-21 North Shore-Long Island Jewish Research Institute Use of hmg fragment as anti-inflammatory agents
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
KR100704158B1 (ko) 2001-11-19 2007-04-05 교와 핫꼬 고교 가부시끼가이샤 다분화능 줄기세포를 조직으로부터 말초혈로 동원하는약제
KR101083454B1 (ko) 2001-12-07 2011-11-16 사이토리 테라퓨틱스, 인크. 처리된 리포애스퍼레이트 세포로 환자를 치료하기 위한 시스템 및 방법
FR2833609B1 (fr) 2001-12-19 2004-12-03 Natural Implant Dispositif de prelevement cellulaire ou tissulaire en phase active et utilisations
ATE427758T1 (de) 2002-07-05 2009-04-15 Univ Laval Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
US20040156851A1 (en) 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
EP1569684A4 (en) 2002-11-20 2006-08-02 Critical Therapeutics Inc USE OF HMGB FRAGMENTS AS ANTI-INFLAMMATORY AGENTS
JP2006517537A (ja) 2003-01-03 2006-07-27 アルケド バイオテック ゲーエムベーハー Ｄｎａ結合タンパク質の使用
CN1193092C (zh) 2003-03-28 2005-03-16 浙江大学 骨髓间充质干细胞分离和体外扩增培养方法
EP1608397B1 (en) 2003-03-28 2008-10-15 Universite Laval S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
US20090069227A9 (en) 2003-04-29 2009-03-12 Capogrossi Maurizio C Use of HMGB1 to promote stem cell migration and/or proliferation
US20050014255A1 (en) 2003-05-29 2005-01-20 Board Of Regents, The University Of Texas System Stem cells for clinical and commercial uses
WO2005025604A2 (en) 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
US7288250B2 (en) 2003-09-11 2007-10-30 Critical Therapeutics, Inc. Monoclonal antibodies against HMGB1
ITRM20040058A1 (it) 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
EP1768693A1 (en) 2004-07-20 2007-04-04 Provincia Italiana Della Congregazione Dei Figli Dell'Immacolata Concezione - Istituto Dermopatico Dell'Immacolata Use of hmgb1 for wound healing
MX2007001155A (es) 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
JP2008520552A (ja) * 2004-10-22 2008-06-19 メディミューン，インコーポレーテッド Ｈｍｇｂ１に対する高親和性の抗体およびその使用法
KR100593397B1 (ko) 2004-10-27 2006-06-28 한국원자력연구소 중배엽 줄기세포 및/또는 ｐ 물질을 함유하는 상처 치유또는 상처 치유 촉진제, 또는 세포 치료제
WO2006047820A1 (en) 2004-11-01 2006-05-11 Newsouth Innovations Pty Limited Use of calgranulin a and b in the promotion and inhibition of mineralized tissue formation
ITRM20050032A1 (it) 2005-01-21 2006-07-22 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di inibire la patogenesi e la progressione della malattia aterosclerotica.
US9782439B2 (en) 2005-01-27 2017-10-10 Japan Health Sciences Foundation Cell sheet containing mesenchymal stem cells
EP1893253B1 (en) 2005-03-23 2010-05-19 Biosafe S.A. Integrated system for collecting, processing and transplanting cell subsets, including adult stem cells, for regenerative medicine
KR100775958B1 (ko) * 2005-03-30 2007-11-13 김정문 조직재생 기능을 가지는 비활성 폴리펩티드 및 그 제조방법
WO2006114805A2 (en) 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
US20100280493A1 (en) 2005-06-23 2010-11-04 Asha Nayak Methods and Systems for Treating Injured Cardiac Tissue
WO2007015546A1 (ja) 2005-08-04 2007-02-08 Genomix Co., Ltd 間葉系幹細胞誘導剤及び組織再生促進剤並びに間葉系幹細胞の調製方法
WO2007031100A1 (en) 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
WO2007061762A2 (en) * 2005-11-18 2007-05-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt And Human Services Non-viral gene delivery complex
WO2007130725A2 (en) * 2006-02-06 2007-11-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of hmgb1 for protection against ischemia reperfusion injury
JP4982739B2 (ja) 2006-06-01 2012-07-25 国立大学法人 東京医科歯科大学 ポリグルタミン病の予防・治療剤
WO2008018641A1 (en) 2006-08-11 2008-02-14 Ono Pharmaceutical Co., Ltd. Monoclonal antibodies against stromal derived factor-1 (sdf-1)
AU2007296843C1 (en) 2006-09-15 2012-08-16 Creabilis Therapeutics S.P.A. Polymer conjugates of Box-A of HMGB1 and Box-A variants of HMGB1
ATE505205T1 (de) * 2006-09-15 2011-04-15 Creabilis Therapeutics Spa Polymerkonjugate von box-a von hmgb1 und box-a- varianten von hmgb1
JP5308161B2 (ja) 2006-10-30 2013-10-09 株式会社ジェノミックス 損傷組織の機能的再生促進医薬
CA2629652A1 (en) 2007-04-24 2008-10-24 Yaojiong Wu Compositions for preventing or treating skin defects and methods of use thereof
US8114668B2 (en) 2007-05-14 2012-02-14 Cardiac Pacemakers, Inc. Composition for cold storage of stem cells
ES2654542T3 (es) * 2008-04-30 2018-02-14 Genomix Co., Ltd. Procedimiento de recolección de células funcionales in vivo con alta eficiencia
CN102076351A (zh) 2008-04-30 2011-05-25 吉诺米克斯股份有限公司 损伤组织的功能性再生促进药物
EP2488209B1 (en) 2009-10-16 2016-09-28 Rutgers, the State University of New Jersey Method for treating chronic nerve tissue injury using a cell therapy strategy
JP5865703B2 (ja) 2009-10-28 2016-02-17 株式会社ジェノミックス 骨髄間葉系および／または多能性幹細胞の血中動員による組織再生促進剤
CN102443064A (zh) 2011-11-03 2012-05-09 刘誉 一种基于凝血酶活性的双靶向作用的嵌合多肽及其应用
SG11201503236RA (en) 2012-10-25 2015-06-29 Genomix Co Ltd Novel method for treating cardiac infarction using hmgb1 fragment
MX365899B (es) 2012-10-25 2019-06-19 Univ Osaka Composición farmacéutica que comprende un fragmento de péptido de hmgb1 para usarse en tratamiento de daño a la medula espinal.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1671742A (zh) * 2002-07-03 2005-09-21 塔博尔山圣拉弗尔基金中心 Hmgb1在治疗组织损伤和/或促进组织修复中的用途
WO2006024547A2 (en) * 2004-09-03 2006-03-09 Creabilis Therapeutics S.P.A. Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use
EP2301559A1 (en) * 2008-04-30 2011-03-30 Genomix Co., Ltd. Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Extracellular HMGB1,a signal of tissue damage,induces mesoangioblast migration and proliferation;Roberta Palumbo et al;《The Journal of Cell Biology》;20040202;第164卷(第3期);第441-449页 *

Also Published As

Publication number Publication date
KR20190073610A (ko) 2019-06-26
HK1258536A1 (en) 2019-11-15
AU2012248676A1 (en) 2013-11-21
AU2019210647B2 (en) 2021-12-23
AU2017203644B2 (en) 2019-05-16
US20200369736A1 (en) 2020-11-26
WO2012147470A1 (ja) 2012-11-01
JP2021191271A (ja) 2021-12-16
EP3358011B1 (en) 2020-03-04
US20140206619A1 (en) 2014-07-24
AU2012248676B2 (en) 2017-04-20
CN107188948A (zh) 2017-09-22
CN103687946A (zh) 2014-03-26
KR20140036202A (ko) 2014-03-25
DK3358011T3 (da) 2020-05-11
CA2834255A1 (en) 2012-11-01
JP2018138049A (ja) 2018-09-06
JP6603964B2 (ja) 2019-11-13
ES2788394T3 (es) 2020-10-21
CN107188948B (zh) 2021-11-30
PT3358011T (pt) 2020-04-23
DK2703487T3 (en) 2018-09-10
US20180072785A1 (en) 2018-03-15
CN114106139B (zh) 2024-08-30
US10364276B2 (en) 2019-07-30
EP2703487A4 (en) 2014-11-12
PL2703487T3 (pl) 2019-03-29
JP2023106525A (ja) 2023-08-01
ES2684718T3 (es) 2018-10-04
EP2703487B1 (en) 2018-06-27
JP2017078067A (ja) 2017-04-27
AU2017203644A1 (en) 2017-06-15
JP2020058344A (ja) 2020-04-16
AU2019210647A1 (en) 2019-08-22
JP6336549B2 (ja) 2018-06-06
EP2703487A1 (en) 2014-03-05
CN114106139A (zh) 2022-03-01
EP3358011A1 (en) 2018-08-08
JP6069191B2 (ja) 2017-02-01
US10550165B2 (en) 2020-02-04
KR102113809B1 (ko) 2020-05-21
KR101992807B1 (ko) 2019-06-26
PT2703487T (pt) 2018-10-11
CA2834255C (en) 2021-11-02
US20230212241A1 (en) 2023-07-06
AU2017203644B9 (en) 2019-06-06
AU2022201894B2 (en) 2024-10-10
AU2022201894A1 (en) 2022-04-07
JPWO2012147470A1 (ja) 2015-02-23
PL3358011T3 (pl) 2020-08-24

Similar Documents

Publication Publication Date Title
CN103687946B (zh) 用于诱导组织再生的肽及其应用
JP6002727B2 (ja) 末梢循環への骨髄由来多能性幹細胞動員薬
HK1240598B (zh) 用於诱导组织再生的肽及其应用
HK1240598A1 (en) Peptide for inducing regeneration of tissue and use thereof
HK1195584A (en) Peptide for inducing regeneration of tissue and use thereof
HK1195584B (en) Peptide for inducing regeneration of tissue and use thereof
HK1195101B (en) Peptide for inducing regeneration of tissue and use thereof
HK1195101A (en) Peptide for inducing regeneration of tissue and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1195584

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1195584

Country of ref document: HK

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Osaka Japan

Co-patentee after: National University Corporation Osaka University

Patentee after: Storm & Co. Ltd.

Address before: Osaka Japan

Co-patentee before: National University Corporation Osaka University

Patentee before: Univ Osaka